VK3019 | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

45 results for “VK3019”

Trials

View all 27 →

Active, not recruiting

NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers

150 participants · First posted Aug 25, 2021

A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)

120 participants · First posted Aug 16, 2024

Putative Cognitive Enhancer VU319

52 participants · First posted Jul 18, 2017

Drugs

View all 14 →

VP301

SKLB-083019

CP-293019

News

Viking's VK2735 Maintains Up to 97% of Weight Loss With Monthly and Biweekly Dosing

Nkarta Prioritizes NKX019 for Autoimmune Diseases, Forgoes Lymphoma Development

Nkarta's NKX019 Cell Therapy Trial Opens Enrollment for ANCA-Associated Vasculitis

Page 1 of 5